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Purpose or Objective: As per published guidelines, SABR is 
the recommended curative treatment option for those stage I 
non-small cell lung cancer patients (NSCLC) who either 
cannot or will not have surgery. This study investigates 
whether patient reported weight loss at presentation is a 
prognostic factor in a retrospective cohort of biopsy-proven 
stage I NSCLC patients who received SABR at one institution. 
 
Material and Methods: Between January 2009 and December 
2013, 314 consecutive patients with histologically proven T1 
or T2a N0 NSCLC treated with SABR were entered in a 
research ethics board approved database. All patients were 
reviewed for potential surgical resection by a thoracic 
surgeon and all had FDG-PET/CT staging. Overall survival (OS) 
by weight loss was evaluated by Kaplan-Meier and log-rank 
test. Univariate and multivariate of weight loss was 
performed using a Cox proportional hazard model; 
adjustment of potential confounders included age, gender, 
performance status, histology, T-stage, tumor location, SUV 
max, smoking status and Charlson Comorbidity Index (CCI).. 
Weight loss was self-reported by patients on a standard 
intake form prior to oncology consultations under 5%, 5-10% 
or greater than 10%. 
 
Results: 292 patients (92.9%) in the database had self-
reported weight loss. 26 (8.9%) and 27 (9.2%) patients self-
reported weight loss of 5-10% or greater than 10%, 
respectively. Survival differences were significant between 
weight loss groups especially in those patients with greater 
than 10% cohort. On univariate analyses, hazard ratio (HR) 
were 0.86 (95%CI 0.41-1.80) and 2.77 (95%CI 1.61-4.79) for 
patients with 5-10% and greater than 10% weight loss, 
respectively. The increased risk of death in patients with 
greater than 10% weight loss remained significant after 
adjustment for all confounders HR= 2.52 (95% CI 1.43-4.45). 
Weight loss overall was a significant risk factor for overall 
survival (P=0.0059). 
 
Conclusion: Patient reported weight loss is a symptom that 
predicts shorter survival even in early stage NSCLC treated 
with SABR. 
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Purpose or Objective: The role of stereotactic ablative 
radiotherapy (SABR) for central tumors is less well 
established due to toxicity concerns. Volumetric modulated 
arc therapy (VMAT) has been used at our center since 2008 to 
deliver risk-adapted SABR for central tumors. We evaluated 
plan quality and clinical outcomes for patients with a central 
tumor. 
 
Material and Methods: We identified 80 consecutive patients 
with primary NSCLC located within 2 cm from the proximal 
bronchial tree (PBT) and treated using RapidArc™ between 
2008-2013. Patients with prior radiotherapy or lung surgery 
were excluded. RTOG definitions were used to contour organs 
at risk (OARs). Compliance to departmental, RTOG 0813 and 
LungTech criteria was assessed for PTV coverage, high/low 
dose spillage and doses delivered to OARs. Long-term toxicity 
results were analysed and overall survival (OS) was compared 
with 252 peripheral tumors (same exclusion criteria) treated 
with 3 or 5 fractions during the same period.  
 
Results: PTV V95 was 60Gy in 96% of patients. Median PTV 
was 66 cm3 (range 9-286). Dmax was ≥60Gy in 40% of patients 
for PBT, 26.3% for aorta, 55% for heart, and 1.3% for trachea. 
Esophageal maximum Dmax was 58Gy. Mean total lung V5Gy 
was 21% and mean total lung V20Gy was 8%. Mean 
contralateral V5Gy was 6.3%. 54 patients (68%) exceeded 
RTOG0813 Dmax for ≥1 organ -at-risk (OAR), with 27 
exceeding PBT Dmax. LungTech OARs dose limits were 
exceeded in 48 patients (60%). 5 of 78 patients (6.4%) with 
adequate follow-up information had grade 3 toxicity. Grade 4 
toxicity was not observed. Treatment-related death was 
considered possible (n=3) or likely (n=3) in 6 patients (7.5%). 
With a median follow-up of 47 months, 3-year survival was 
53%, compared with 57% for 252 peripheral tumors treated 
with 3 or 5 fractions SABR in the same period (p=0.369).  
 
Conclusion: Although a substantial proportion of moderately 
central SABR patients received ≥60Gy to OARs, the 3 -year 
survival was similar to patients with peripheral tumors. OARs 
tolerance doses continue to be refined and patients should be 
informed of the potential risks and benefits of central lung 
SABR. In the meantime, it appears reasonable to limit Dmax 
in OARs (including inside PTV) and lung doses (e.g. V5), using 
IMRT/VMAT. It is finally important to note that the outcomes 
in the present analysis should not be extrapolated to very 
central tumors, where the toxicity risks may be higher. 
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Purpose or Objective: A novel liquid gel fiducial marker 
(BioXmark®) was developed for use in image guided 
radiotherapy (IGRT).  
The injectable marker is based on three components; sucrose 
acetate isobutyrate (SAIB), x-SAIB (electron dense SAIB 
analogue) and ethanol. After injection, the liquid gel matrix 
rapidly increases viscosity forming a rigid hydrophobic 
gel.with minimal degradation over months (animal studies). 
The marker was developed as an alternative to solid metal 
fiducial markers, providing a simpler injection procedure and 
potentially lowering the risk of 
complications/displacement/marker loss while remaining 
visible on ultrasound, 2D kV X-ray/CT and MRI images. 
In this study, we investigated the safety and feasibility of 
endoscopic (bronchial) ultrasound (EUS/EBUS) guided 
injection of the liquid marker into patients with stage III non-
small cell lung cancer (NSCLC), and the visibility of the 
marker throughout the radiotherapy (RT) course. 
 
Material and Methods: Patients with stage III NSCLC referred 
for concomitant chemo-RT (66 Gy in 33 fractions) were 
eligible.  
Marker injection was done by experienced pulmonologists as 
an outpatient procedure. Standard EUS and EBUS equipment 
with a 22G aspiration needle was used for injection.  
Marker deposits were injected in the primary tumour (if 
possible) and affected mediastinal lymph nodes. The 
